PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

  • days left to enroll
  • participants needed
  • sponsor
    University of Alabama at Birmingham
Updated on 11 May 2021
adjuvant therapy
her2/neu-positive breast cancer


Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response to HER2 therapy.

Condition Breast Cancer, Breast Cancer Diagnosis, breast carcinoma, cancer, breast
Treatment [89Zr]-Df-Trastuzumab, PET/MRI Imaging
Clinical Study IdentifierNCT03321045
SponsorUniversity of Alabama at Birmingham
Last Modified on11 May 2021


Yes No Not Sure

Inclusion Criteria

Adult female patients (n=10) with biopsy-proven HER2-positive, with at least one FDG positive lesion by PERCIST
Be at least 18 years of age
Patients eligible for neoadjuvant therapy using a regimen containing at least one anti-HER2 agent (stage 2 and 3 HER2+ breast cancer)
ECOG performance status of 0 and 1
Ejection fraction greater than 50% by echocardiogram or MUGA scans
Be enrolled in the I-SPY 2 trial

Exclusion Criteria

Pregnant women and patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or unable to tolerate up to 60 min of PET imaging per imaging session
Inability to provide informed consent
Weight over 350 lbs., due to the scanner bore size
Contraindication for MRI study (non-removable metal implants or certain tattoos)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note